R&D | Cutting-edge science and innovative research

News

Novo unveils first data for 'triple G' agonist in diabetes

Novo Nordisk has reported the first clinical data with its triple G agonist for diabetes, in China, as it starts an international trials programme.

News

AI in drug discovery and development: news watch

Recent developments in the biopharma AI world include a big financing for Verily, and updates from Zealand, Latent Labs, Insilico, and BMS/insitro.

News

Update: Rumour confirmed as MSD buys Terns for $6.7bn

MSD's glut of pipeline-boosting deals in the build-up to a looming patent cliff has continued with a $6.7bn bid to acquire Terns Pharma.

News

Karyopharm eyes Xpovio filing in myelofibrosis on mixed data

Despite hitting just one of two efficacy endpoints in a pivotal trial, Karyopharm thinks it still has a path to approval for Xpovio in myelofibrosis.

News

MSD taps Quotient for IBD drug targets in $2.2bn deal

MSD is paying $20m upfront to activate an alliance with Flagship's Quotient Therapeutics to find new targets in inflammatory bowel disease.

News

GSK chases down Pfizer in 5-in-1 meningitis jab contest

Armed with new data, GSK is preparing to file for approval of its new-generation meningitis vaccine, as it tries to maintain its leadership in the category against a chall

News

After FDA snub, DBV charts a new course for Viaskin peanut

It’s been more than three years since DBV Technologies’ peanuty allergy therapy was

R&D

Health Innovators – Fady Malik and Steve Heitner

In this instalment of Health Innovators, EiC Jonah Comstock sits down virtually with Fady Malik, EVP of research and development at Cytokinetics and Steve Heitner, the company’s VP of clinical rese

Debates & Insights

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Webinars

Sponsored

Synthetic control arms in clinical trials: Making it happen

Across the industry, pharma companies are turning to AI and real-world data to address many of the challenges of running clinical trials.

Webinars

Sponsored

How synthetic control arms are changing clinical trials

Clinical trials are involved, expensive, and have been done largely the same way for decades but with today’s technology all that can change. With drawn-out timelines and billions

News

Novo unveils first data for 'triple G' agonist in diabetes

Novo Nordisk has reported the first clinical data with its triple G agonist for diabetes, in China, as it starts an international trials programme.

News

AI in drug discovery and development: news watch

Recent developments in the biopharma AI world include a big financing for Verily, and updates from Zealand, Latent Labs, Insilico, and BMS/insitro.

Press Releases

Views & Analysis

Touring Chiesi's vision for the future at the new Biotech Ce...

Following an invite to fly into Parma, Italy to witness first-hand the press launch of the considerable structure – black-painted and as yet under construction, gigantic cranes and all – th

News

Vir awarded $1 billion multi-year BARDA influenza contract

The US Government’s Biomedical Advanced Research and Development Authority (BARDA) has made an

Views & Analysis

R&D

Interview at BIO-Europe 2026 with Robert Jacks

BIO-Europe Spring 2026: In conversation with Robert Jacks

R&D

Supporting the ageing process, pharmaceutically

Longevity is not a consumer trend, but a pipeline strategy p...

Longevity is being framed as a consumer movement when, in reality, it is a pharmaceutical pipeline challenge.

R&D

pharmaphorum podcast Episode 250, Rob DiCicco, Transcelerate

Making AI work where it matters, with Rob DiCicco

Rob DiCicco, vice president of portfolio management at Transcelerate Biopharma Inc, discusses barriers and the breakthroughs in making AI work.

Deep Dive

R&D

The GLP-1 Reckoning

R&D

Designing obesity trials around real lives: How patient cent...

R&D

Beyond obesity: How GLP-1s are changing the game for hundred...

R&D

Sponsored

Exploring the future: Opportunities and challenges in cell a...

Rare disease treatment poses distinct challenges for physicians, patients, caregivers, and pharma companies.

R&D

Sponsored

Beyond clinical: Boosting recruitment and retention with SDO...

The success of clinical trials hinges on a complex array of factors, many of which extend beyond traditional clinical care.

R&D

evolution of clinical research in the UK

Sponsored

The evolution of clinical research: Embracing new delivery m...

The UK is welcoming a new era of clinical trial delivery, evolving beyond the traditional site-centric approach to also embrace remote, decentralised, virtual, and hybrid trials and enablin

Podcasts

R&D

Making AI work where it matters, with Rob DiCicco

Rob DiCicco, vice president of portfolio management at Transcelerate Biopharma Inc, discusses barriers and the breakthroughs in making AI work.

R&D

pharmaphorum podcast Episode 249, Michelle Werner, Alltrna

Treating genetic disease at scale with tRNA, with Michelle W...

Michelle Werner, Director of Alltrna, discusses her company’s approach of leveraging transfer RNA (tRNA) to shift the paradigm in genetic medicine.

R&D

pharmaphorum podcast Episode 248, Andrew Mackinnon, Medable

AI in clinical development & ‘white space’, with Andrew Mack...

Andrew Mackinnon, senior vice president and executive general manager at Medable, discusses leveraging AI to transform & accelerate development.

Video

R&D

BIO-Europe Spring 2026: In conversation with Robert Jacks

R&D

Treating the chronic diseases GLP-1s miss, with Laurent Auda...

Prive Bio CEO Laurent Audaly spoke with pharmaphorum during the JP Morgan Healthcare conference, discussing GLP-1s in the cardiometabolic space.

R&D

The long-delayed promise of the microbiome, with Sam Possemi...

Sam Possemiers, CEO of MRM Health, believes that the microbiome space is finally coming into maturity.

White Papers

R&D

A man stood on a rock looking towards the horizon

Sponsored

A New Framework to Engineer Breakthrough Value for Medicines

A new white paper from Lumanity – ‘A New Framework to Engineer Breakthrough Value for Medicines: Value Inflection Points Across the Development Path’.

R&D